Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Audrey J. Muscato Clear advanced filters

  • CAR T cell therapies are effective but costly and difficult to manufacture. Here, authors develop a novel approach using retargeted and functionalized lentiviral vectors that selectively reprogram T cells in vivo, evade immune clearance, and generate functional CAR T cells with therapeutic efficacy.

    • Kyrellos E. Ibrahim
    • Kepler S. Mears
    • Robert T. Manguso
    ResearchOpen Access
    Nature Communications
    P: 1-17

  • UCHL5 is a deubiquitinating enzyme that cleaves Lys-48-linked polyubiquitin chains. Here, the authors discover through in-vivo CRISPR-Cas9 screens that Uchl5 is involved in immune evasion and modulation of extracellular matrix deposition in head and neck squamous cell carcinoma.

    • Cong Fu
    • Robert Saddawi-Konefka
    • Robert T. Manguso
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-18

  • An orally bioavailable small-molecule active-site inhibitor of the phosphatases PTPN2 and PTPN1, ABBV-CLS-484, demonstrates immunotherapeutic efficacy in mouse models of cancer resistant to PD-1 blockade.

    • Christina K. Baumgartner
    • Hakimeh Ebrahimi-Nik
    • Robert T. Manguso
    ResearchOpen Access
    Nature
    Volume: 622, P: 850-862

  • CAR-T therapy is a promising treatment modality for B-cell malignancies, yet many patients relapse. Using an in vivo genomewide screen in a model of B cell leukemia, we identify an unexpected mechanism of CAR-T resistance in which interferon gamma from the in vivo tumor microenvironment induces an adaptive T-cell resistance program in tumor cells.

    • Azucena Ramos
    • Catherine E. Koch
    • Michael T. Hemann
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-21

  • Here, the authors use genome-scale in vivo CRISPR screens to look at immune evasion mechanisms across cancer models, showing that IFN-mediated upregulation of classical and non-classical MHC class I inhibitory checkpoints facilitate immune escape.

    • Juan Dubrot
    • Peter P. Du
    • Robert T. Manguso
    Research
    Nature Immunology
    Volume: 23, P: 1495-1506